检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial

Meletios A. Dimopoulos,Katja Weisel,Sagar Lonial,Darrell White,Philippe Moreau,Maria-Victoria Mateos,Jesus San-Miguel,Kenneth C. Anderson,Ofer Shpilberg,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Andrew Belch,Donna Reece,Meral Beksac,Alex Ganetsky,Ying-Ming Jou,Mihaela Popa McKiver,Anil K. Singhal,Paul G. Richardson

Clinical Lymphoma Myeloma and Leukemia（2019）

引用 6|浏览62
暂无评分
关键词
elotuzumab,Overall survival,relapsed/refractory multiple myeloma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要